TY - JOUR
T1 - The predictive role of plasma TGF-β1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer
AU - Zhao, Lujun
AU - Sheldon, Kerby
AU - Chen, Ming
AU - Yin, Moli S.
AU - Hayman, James A.
AU - Kalemkerian, Gregory P.
AU - Arenberg, Doug
AU - Lyons, Susan E.
AU - Curtis, Jeffrey L.
AU - Davis, Mary
AU - Cease, Kemp B.
AU - Brenner, Dean
AU - Anscher, Mitchell S.
AU - Lawrence, Theodore S.
AU - Kong, Feng Ming
PY - 2008/2/1
Y1 - 2008/2/1
N2 - Background: This study aimed to further investigate the role of circulating TGF-β1 during radiation therapy (RT) in predicting radiation-induced lung toxicity (RILT). Methods and materials: Patients with stages I-III non-small cell lung cancer treated with RT based therapy were included in this study. Platelet poor plasma was obtained pre-RT, at 2 and 4 weeks during-RT, and at the end of RT. TGF-β1 was measured using an enzyme-linked immunosorbent assay. The primary endpoint for RILT was ≥grade 2 radiation pneumonitis or fibrosis. Results: Twenty-six patients with a minimum follow-up of 12 months were included. Six patients (23.1%) experienced ≥grade 2 RILT. There was no significant difference in absolute TGF-β1 levels pre-RT, at 2 and 4 weeks during-RT, or at the end of RT between patients with and without RILT. The TGF-β1 ratios (over the pre-RT levels) for patients with and without RILT at 2, 4 weeks during-, and the end of RT were 2.8 ± 2.2 and 1.0 ± 0.6 (P = 0.123), 2.3 ± 1.3 and 0.8 ± 0.5 (P = 0.001), 1.5 ± 0.9 and 0.8 ± 0.5 (P = 0.098), respectively. Using 2.0 as a cut-off, the TGF-β1 ratio at 4 weeks during-RT predicted RILT with a sensitivity and specificity of 66.7% and 95.0%, respectively. Conclusion: Elevation of plasma TGF-β1 level 4 weeks during-RT is significantly predictive of RILT. The role of plasma TGF-β1 in predicting RILT deserves further study.
AB - Background: This study aimed to further investigate the role of circulating TGF-β1 during radiation therapy (RT) in predicting radiation-induced lung toxicity (RILT). Methods and materials: Patients with stages I-III non-small cell lung cancer treated with RT based therapy were included in this study. Platelet poor plasma was obtained pre-RT, at 2 and 4 weeks during-RT, and at the end of RT. TGF-β1 was measured using an enzyme-linked immunosorbent assay. The primary endpoint for RILT was ≥grade 2 radiation pneumonitis or fibrosis. Results: Twenty-six patients with a minimum follow-up of 12 months were included. Six patients (23.1%) experienced ≥grade 2 RILT. There was no significant difference in absolute TGF-β1 levels pre-RT, at 2 and 4 weeks during-RT, or at the end of RT between patients with and without RILT. The TGF-β1 ratios (over the pre-RT levels) for patients with and without RILT at 2, 4 weeks during-, and the end of RT were 2.8 ± 2.2 and 1.0 ± 0.6 (P = 0.123), 2.3 ± 1.3 and 0.8 ± 0.5 (P = 0.001), 1.5 ± 0.9 and 0.8 ± 0.5 (P = 0.098), respectively. Using 2.0 as a cut-off, the TGF-β1 ratio at 4 weeks during-RT predicted RILT with a sensitivity and specificity of 66.7% and 95.0%, respectively. Conclusion: Elevation of plasma TGF-β1 level 4 weeks during-RT is significantly predictive of RILT. The role of plasma TGF-β1 in predicting RILT deserves further study.
KW - Lung cancer
KW - Radiation therapy
KW - Radiation-induced lung toxicity
KW - Transforming growth factor β1
UR - http://www.scopus.com/inward/record.url?scp=38649099697&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38649099697&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2007.08.010
DO - 10.1016/j.lungcan.2007.08.010
M3 - Article
C2 - 17905467
AN - SCOPUS:38649099697
VL - 59
SP - 232
EP - 239
JO - Lung Cancer
JF - Lung Cancer
SN - 0169-5002
IS - 2
ER -